T. Rowe Price Investment Management
BCAX

T. Rowe Price Investment Management’s Bicara Therapeutics BCAX Stock Holding History

T. Rowe Price Investment Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$188M Sell
6,338,487
-267,293
-4% -$5.97M 0.12% 188
2026
Q1 		$131M Buy
6,605,780
+3,369,185
+104% +$58M 0.09% 212
2025
Q4 		$54.5M Buy
3,236,595
+2,771,868
+596% +$47.3M 0.03% 350
2025
Q3 		$7.34M Buy
+464,727
New +$5.2M ﹤0.01% 568

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management's BCAX Position: Q2 2026 in Review

T. Rowe Price Investment Management reduced its Bicara Therapeutics (BCAX) stake by 4% in Q2 2026, selling an estimated $5.97M and leaving 6,338,487 shares worth $188M. The position accounts for 0.12% of the portfolio, ranked #188.

T. Rowe Price Investment Management first reported a position in BCAX in Q3 2025 and has held it in 4 quarters since. 171 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • T. Rowe Price Investment Management held 6,338,487 shares of Bicara Therapeutics worth $188M as of Q2 2026.
  • T. Rowe Price Investment Management sold 267,293 Bicara Therapeutics shares in Q2 2026, an estimated $5.97M.
  • Bicara Therapeutics made up 0.12% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #188 holding.
  • T. Rowe Price Investment Management first reported a position in Bicara Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 171 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.